New FDA Guidance on Cannabis Research and Accurate Labeling for Consumers

By: Sofiya Cherbukhovsky, RN, BSN | Certified Cannabis Nurse | Plesio Health

The cannabis industry has been growing rapidly over the past few years, with more and more states legalizing its use for both medical and recreational purposes. However, the industry has also faced challenges, particularly in the realm of regulation and labeling. In recent news, the FDA has provided guidance on conducting clinical research with cannabis or cannabis-derived products, which aims to clarify the agency’s expectations for research in this area.

The guidance explains that any clinical investigation of a cannabis or cannabis-derived product must receive FDA approval before it can begin. This means that researchers must submit an investigational new drug (IND) application to the FDA before conducting any clinical research.

The FDA also provides guidance on specific issues related to cannabis research, including:

  • Drug development and approval: The FDA requires that any clinical research on cannabis or cannabis-derived products must follow the same drug development and approval process as other drugs. This involves demonstrating safety and efficacy through clinical trials before FDA approval is granted.
  • Quality and consistency: The FDA emphasizes the importance of quality and consistency in cannabis-derived products used in clinical research. Researchers are expected to use products that are manufactured in compliance with Good Manufacturing Practices (GMPs) and to use validated analytical methods to measure the concentration of cannabinoids and other active ingredients in the products.
  • Study design: The FDA provides guidance on the design of clinical studies with cannabis-derived products, including patient selection, dosing, and endpoints. Researchers are encouraged to develop well-designed studies that can generate high-quality data.
  • Adverse events reporting: The FDA requires researchers to report any adverse events associated with the use of cannabis-derived products in clinical research. This helps the FDA monitor the safety of these products and make informed decisions about their regulation.

Overall, the FDA’s guidance aims to provide clarity to researchers conducting clinical research with cannabis or cannabis-derived products. By adhering to this guidance, researchers can ensure that their studies are conducted safely and with the highest scientific standards.

The FDA recognizes that the current regulatory frameworks for foods and supplements are not suitable for CBD products. Thus, the agency is developing a regulatory framework that can address the safety and effectiveness of CBD products manufactured for sale in the U.S.

The lack of labeling requirements for cannabis and CBD products is a significant issue, as it makes it difficult for consumers to know exactly what they are buying and using. This lack of information on labels can be especially concerning for people with health conditions who are using CBD products to manage symptoms, as they may be unaware of potential risks or interactions. Additionally, inconsistent labeling and marketing claims have led to confusion and misinformation among consumers, making it difficult for them to make informed decisions about which products to use.

To address this issue, here are some key points to keep in mind:

  • Currently, the FDA does not require manufacturers to include specific information on the label, such as the amount of CBD in the product, the source of the CBD, or any potential side effects or interactions with other medications.
  • The FDA intends to develop regulations that require accurate and informative labeling for CBD products in the future.
  • Consumers are encouraged to consult with a medical cannabis provider, such as a cannabis nurse or physician, to get a better understanding of the potential risks and benefits of using CBD products.
  • It is important to purchase products from reputable manufacturers who provide clear and transparent labeling, as inconsistent labeling and marketing claims can lead to confusion and misinformation among consumers.

Overall, the future of the cannabis industry with the FDA is still uncertain, but there are promising signs that suggest positive changes are on the horizon. The FDA has already approved one cannabis-based drug, Epidiolex, for the treatment of epilepsy, and is currently evaluating others for various medical conditions.

With public opinion and scientific evidence on its side, the cannabis industry is poised for a bright future, but its success will ultimately depend on the government’s willingness to embrace change and adapt to new realities.

Scroll to Top